Matica Biotechnology to Manufacture HSV Vectors for Treovir's Pediatric Brain Tumor Therapy
Key Insights
Matica Biotechnology (search), a subsidiary of CHA Biotech (search), has partnered with Treovir (search) to manufacture herpes simplex virus (search) (HSV) vectors for pediatric brain tumor (search) therapy.
The collaboration supports Treovir (search)'s Phase 2 clinical trial of G207, an HSV-based oncolytic therapy, involving 30 pediatric brain tumor (search) patients.
Treovir (search)'s G207 has received orphan drug designation in the U.S. and Europe, along with fast-track designation from the FDA, highlighting its potential impact.
Matica Biotechnology (search), the U.S.-based CDMO subsidiary of CHA Biotech (search), has entered into an agreement with Treovir (search) to manufacture herpes simplex virus (search) (HSV) vectors for Treovir's oncolytic immunotherapy, G207, which targets pediatric brain tumors. This collaboration aims to support the ongoing Phase 2 clinical trial of G207.
The partnership focuses on the GMP manufacturing of clinical supplies for Treovir (search)'s G207, an HSV-based oncolytic therapy currently being evaluated in a Phase 2 clinical trial involving 30 pediatric brain tumor (search) patients. The trial is designed to assess the safety, immune response, and radiation response of G207 in children with brain tumors.
G207: A Promising Therapy for Pediatric Brain Tumors
G207 has been granted orphan drug designation in both the United States and Europe, as well as fast-track designation from the U.S. Food and Drug Administration (FDA). These designations underscore the urgent need for effective treatments for pediatric brain tumors and the potential of G207 to address this unmet need.
Michael Christini, CEO of Treovir (search), stated, "Finding a CDMO partner who truly understands our mission and works alongside us as an extension of our team is essential for successful drug development. We are collaborating with Matica Bio on process optimization and production for G207, and we look forward to advancing this promising therapy for pediatric brain tumors, with Matica Bio playing a key role."
Matica Bio's Role in Cell and Gene Therapy Manufacturing
CHA Biotech (search) established Matica Biotechnology (search) to enter the U.S. cell and gene therapy CDMO market. In 2022, Matica Biotechnology became the first biotech from Korea to establish a CDMO facility in Texas. The company's expertise in viral vector manufacturing and cell therapy product development makes it a valuable partner for Treovir (search) in advancing G207.
Paul Kim, CEO of Matica Biotechnology (search), commented, "We are thrilled to partner with Treovir (search) in this important effort. Pediatric rare diseases represent an area of critical need, and Matica Bio is proud to contribute to the mission of improving the lives of these children."